These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31120709)

  • 1. Potential impact of pharmaceutical industry rebates on medication adherence.
    Zullig LL; Granger BB; Vilme H; Oakes MM; Bosworth HB
    Am J Manag Care; 2019 May; 25(5):e135-e137. PubMed ID: 31120709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
    Dusetzina SB; Conti RM; Yu NL; Bach PB
    JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
    Yeung K; Dusetzina SB; Basu A
    JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Out-of-pocket spending on drugs and pharmaceutical products and cost-related prescription non-adherence among Canadians with chronic disease.
    Hennessy D; Sanmartin C; Ronksley P; Weaver R; Campbell D; Manns B; Tonelli M; Hemmelgarn B
    Health Rep; 2016 Jun; 27(6):3-8. PubMed ID: 27305075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What Determines How Much Your Patient Pays for Their Medication in the United States?
    Novack GD
    Am J Ophthalmol; 2016 Jul; 167():48-51. PubMed ID: 27131775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of pharmaceutical rebates on patients' drug expenditures.
    Memedovich KA; Manns B; Beall R; Hollis A; Clement F
    CMAJ; 2019 Mar; 191(11):E308-E312. PubMed ID: 30885969
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.
    Lakdawalla D; Li M
    JAMA Netw Open; 2021 May; 4(5):e219030. PubMed ID: 33950205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consumer Out-Of-Pocket Drug Prices Grew Faster Than Prices Faced By Insurers After Accounting For Rebates, 2007-20.
    Mallatt J; Dunn A; Fernando L
    Health Aff (Millwood); 2024 Sep; 43(9):1284-1289. PubMed ID: 39226496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Patient Reimbursement Timing and Patient Out-of-Pocket Expenses on Medication Adherence in Patients Covered by Private Drug Insurance Plans.
    Després F; Forget A; Kettani FZ; Blais L
    J Manag Care Spec Pharm; 2016 May; 22(5):539-47. PubMed ID: 27123915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier?
    Sarnak DO; Squires D; Kuzmak G; Bishop S
    Issue Brief (Commonw Fund); 2017 Oct; 2017():1-14. PubMed ID: 28990747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect Of Veterans Health Administration Coverage On Cost-Related Medication Nonadherence.
    Gaffney A; Bor DH; Himmelstein DU; Woolhandler S; McCormick D
    Health Aff (Millwood); 2020 Jan; 39(1):33-40. PubMed ID: 31905070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
    Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
    JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How do state Medicaid programs determine what substance use disorder treatment medications need prior authorization? An overview for clinicians.
    Bachhuber MA
    Addict Sci Clin Pract; 2020 Jun; 15(1):20. PubMed ID: 32600402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums.
    Starner CI; Alexander GC; Bowen K; Qiu Y; Wickersham PJ; Gleason PP
    Health Aff (Millwood); 2014 Oct; 33(10):1761-9. PubMed ID: 25288420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.
    Wong WB; Seetasith A; Hung A; Zullig LL
    PLoS One; 2023; 18(1):e0280570. PubMed ID: 36656871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical Cost-Saving Strategies and their Association with Medication Adherence in a Medicare Supplement Population.
    Musich S; Cheng Y; Wang SS; Hommer CE; Hawkins K; Yeh CS
    J Gen Intern Med; 2015 Aug; 30(8):1208-14. PubMed ID: 25666213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies Used by Adults Aged 65 and Over to Reduce Their Prescription Drug Costs, 2016-2017.
    Cohen RA; Boersma P
    NCHS Data Brief; 2019 May; (335):1-8. PubMed ID: 31163016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Has The Era Of Slow Growth For Prescription Drug Spending Ended?
    Aitken M; Berndt ER; Cutler D; Kleinrock M; Maini L
    Health Aff (Millwood); 2016 Sep; 35(9):1595-603. PubMed ID: 27605638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do interventions that address patient cost-sharing improve adherence to prescription drugs? A systematic review of recently published studies.
    Sensharma A; Yabroff KR
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):263-277. PubMed ID: 30628493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.